Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-03-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团十届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 14th meeting of the 10th board, including approval of a 2023 guarantee plan and the proposal to convene a 2023 second extraordinary shareholders meeting. The document is short (834 characters) and primarily announces board decisions rather than providing detailed financial data or full reports. It does not contain financial statements or comprehensive management discussion. It is not an annual or interim report, nor an earnings release. It is not a regulatory filing or certification. The content fits best under Board/Management Information (MANG) as it announces board resolutions and related corporate governance matters.
2023-03-28 Chinese
昆药集团独立董事对公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent director's special statement and opinion on the company's external guarantees for the year ending December 31, 2022. It includes extensive data on guarantee amounts, counterparties, contract terms, and compliance with regulatory requirements. The content focuses on the review and audit of external guarantees and the independent directors' opinions on their legality and compliance. There is no indication that this is a full annual report, audit report, or financial statement. Instead, it is a specialized report related to audit and compliance of external guarantees, which aligns with the definition of an Audit Report / Information (AR). The document length is substantial (9679 characters), and it contains detailed substantive information rather than just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2022
2023-03-22 Chinese
昆药集团2022年度社会责任报告
Regulatory Filings
2023-03-22 Chinese
昆药集团关于2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Kunming Pharmaceutical Group Co., Ltd. regarding the annual deposit and actual use of raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. The content includes detailed financial figures about the amounts raised through various stock issuances (initial public offering, additional issuance, and private placement), the timing of fund receipt, usage amounts in previous and current years, balances, and investment projects funded by these raised funds. It also discusses the management system for raised funds, the establishment of special accounts for these funds, and the use of idle funds for cash management and investment products. The document is comprehensive, covering multiple years up to December 31, 2022, and includes tables and notes on fund usage and project progress. This type of document is a specialized report on capital raising and fund usage, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or audit report, but a focused report on fundraising and capital management activities. Therefore, the appropriate classification is CAP with high confidence.
2023-03-22 Chinese
昆药集团十届十三次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Corporation Limited regarding several board meeting agenda items. It references internal control evaluation, profit distribution plan, special report on raised funds usage, asset impairment provisions, personnel remuneration, and stock repurchase related to a restricted stock incentive plan. The document is not a full annual report or financial statement but rather an independent directors' review and opinion on board matters, including compliance with laws and regulations. It is not a simple announcement or certification but a detailed governance-related opinion on board resolutions. This fits best under Board/Management Information (MANG), as it concerns board meeting matters and independent directors' opinions on company governance and decisions.
2023-03-22 Chinese
昆药集团十届十三次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. It details the approval of various reports and proposals related to the company's 2022 fiscal year, including the Supervisory Board's work report, internal control evaluation report, internal control audit report, annual report, social responsibility report, financial settlement report, profit distribution plan, and other related matters. The document is not the reports themselves but an announcement of the Supervisory Board's resolutions and opinions on these reports and proposals. It also references that the full reports are published on the Shanghai Stock Exchange website, indicating this document serves as an official announcement of these resolutions rather than the reports themselves. The document length is 2147 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and approvals related to various reports, not the reports themselves.
2023-03-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.